Ph-Positive Acute Lymphoblastic Leukemia Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has increased survival, with high-level clearance of measurable tumor cells.
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia / Foà, Robin; Chiaretti, Sabina. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 386:25(2022), pp. 2399-2411. [10.1056/nejmra2113347]
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Foà, Robin;Chiaretti, Sabina
2022
Abstract
Ph-Positive Acute Lymphoblastic Leukemia Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has increased survival, with high-level clearance of measurable tumor cells.File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
